Teva Pharmaceutical Industries Company Description
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally.
The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas.
Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease.
The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease.
Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim.
Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia.
The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
| Country | United States |
| Founded | 1901 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 35,686 |
| CEO | Richard Francis |
Contact Details
Address: 124 Dvora HaNevi’a St. Tel Aviv Israel | |
| Phone | 972 3 914 8213 |
Stock Details
| Ticker Symbol | TEVJF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | IL0006290147 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard D. Francis | President, Chief Executive Officer and Director |
| Eliyahu Sharon Kalif | Executive Vice President and Chief Financial Officer |
| Mark Sabag | Executive Vice President of International Markets Commercial |
| Richard Gordon Daniell | Executive Vice President of European Commercial |
| Matthew Shields | Executive Vice President of Global Operations |
| Amir Weiss | Senior Vice President and Chief Accounting Officer |
| Christopher J. Stevo CFA | Senior Vice President of Investor Relations and Competitive Intelligence |
| Kathleen Veit | Senior Vice President, Global Compliance and Ethics Officer |
| David R. Mcavoy J.D. | Executive Vice President and Chief Legal Officer |
| Placid Jover | Executive Vice President and CHRO |